|
Oxford BioDynamics PLC on Thursday announced an expanded strategic agreement with UK health insurance provider Bupa. The stock closed 9.7% higher at 0.52 pence per share on Thursday in London. Oxford BioDynamics, an Oxford, England-based biotechnology company, said that Bupa UK insurance customers with a raised prostate-specific antigen level and no additional high risk factors or symptoms will now be covered for its EpiSwitch PSE prostate cancer blood test. Expanding the partnership, with Bupa customers already covered for the EpiSwitch CiRT or checkpoint inibitor response test - which accurately predicts individual cancer patients’ therapeutic responses to immune checkpoint inhibitors - ‘significantly enhances access to PSE in the UK’, Oxford BioDynamics said. ‘Joining forces with a pioneering healthcare insurer like Bupa ensures that more men have access to an accurate diagnosis by using the EpiSwitch PSE test,’ commented Oxford BioDynamics Executive Chair Iain Ross. ‘Prostate cancer is the most common cancer in men in the UK, and yet there is currently no nationwide screening programme due to limitations of current testing modalities. ‘With its high accuracy and PPV, EpiSwitch PSE can be integrated into existing pathways to more precisely direct individuals toward further expensive and invasive diagnostics and treatments. We remain focused on forging strategic partnerships to build on this momentum and continue to drive value.’ Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
